ScholarLens Back to search
2023•Annals of HematologyOpen access

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response

Amanda Pifano Soares Ferreira, Fernanda Salles Seguro, André Ramires Neder Abdo, Fernanda Maria Santos, Felipe Vieira Rodrigues Maciel, Luciana Nardinelli, Ricardo Rodrigues Giorgi, Antonio Roberto Lancha Ruiz, Milton P. Ferreira, Eduardo Magalhães Rego, Vanderson Rocha, Israel Bendit

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Imatinib mesylate, Myeloid leukemia, Hematology, Imatinib, Medicine, Internal medicine, Oncology, Intensive care medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response — Research Paper | ScholarLens